Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Firdapse® (amifampridine) – Expanded indication
September 29, 2022 - Catalyst Pharmaceuticals announced the FDA approval of Firdapse (amifampridine), for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
